ASH Meeting on Hematologic Malignancies

ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions

Daratumumab Has Favorable Safety Profile in Relapsed/Refractory Multiple Myeloma Patients

Friday, January 6th, 2017
For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, management of infusion-related reactions (IRRs) required temporary slowing or stopping of...

Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma

Saturday, November 26th, 2016
Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...

Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival

Saturday, October 1st, 2016
Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...

Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials

Saturday, October 1st, 2016
Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...

TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes

Saturday, October 1st, 2016
The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.